GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Luye Pharma Group Ltd (HKSE:02186) » Definitions » Gross Margin %

Luye Pharma Group (HKSE:02186) Gross Margin % : 69.80% (As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Luye Pharma Group Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Luye Pharma Group's Gross Profit for the six months ended in Dec. 2023 was HK$2,473 Mil. Luye Pharma Group's Revenue for the six months ended in Dec. 2023 was HK$3,543 Mil. Therefore, Luye Pharma Group's Gross Margin % for the quarter that ended in Dec. 2023 was 69.80%.

Warning Sign:

Luye Pharma Group Ltd gross margin has been in long-term decline. The average rate of decline per year is -3%.


The historical rank and industry rank for Luye Pharma Group's Gross Margin % or its related term are showing as below:

HKSE:02186' s Gross Margin % Range Over the Past 10 Years
Min: 65.32   Med: 77.21   Max: 81.66
Current: 68.44


During the past 13 years, the highest Gross Margin % of Luye Pharma Group was 81.66%. The lowest was 65.32%. And the median was 77.21%.

HKSE:02186's Gross Margin % is ranked better than
82.89% of 988 companies
in the Drug Manufacturers industry
Industry Median: 46.48 vs HKSE:02186: 68.44

Luye Pharma Group had a gross margin of 69.80% for the quarter that ended in Dec. 2023 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Luye Pharma Group was -3.00% per year.


Luye Pharma Group Gross Margin % Historical Data

The historical data trend for Luye Pharma Group's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Luye Pharma Group Gross Margin % Chart

Luye Pharma Group Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 76.74 72.04 65.32 69.22 68.44

Luye Pharma Group Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 64.18 71.91 66.77 66.92 69.80

Competitive Comparison of Luye Pharma Group's Gross Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Luye Pharma Group's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Luye Pharma Group's Gross Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Luye Pharma Group's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Luye Pharma Group's Gross Margin % falls into.



Luye Pharma Group Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Luye Pharma Group's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )=Gross Profit (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=4598.4 / 6719.169
=(Revenue - Cost of Goods Sold) / Revenue
=(6719.169 - 2120.731) / 6719.169
=68.44 %

Luye Pharma Group's Gross Margin for the quarter that ended in Dec. 2023 is calculated as


Gross Margin % (Q: Dec. 2023 )=Gross Profit (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=2472.8 / 3542.717
=(Revenue - Cost of Goods Sold) / Revenue
=(3542.717 - 1069.889) / 3542.717
=69.80 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Luye Pharma Group  (HKSE:02186) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Luye Pharma Group had a gross margin of 69.80% for the quarter that ended in Dec. 2023 => Durable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Luye Pharma Group Gross Margin % Related Terms

Thank you for viewing the detailed overview of Luye Pharma Group's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Luye Pharma Group (HKSE:02186) Business Description

Traded in Other Exchanges
Address
No. 15 Chuang Ye Road, High-tech Industrial Development Zone, Shandong, Yantai, CHN, 264003
Luye Pharma Group Ltd is a China-based drug manufacturer that focuses on developing, producing, and selling pharmaceutical products. The company develops drugs related to diagnosing and treating cancer, the cardiovascular system, the alimentary tract, and the central nervous system. The company's highest revenue share comes from oncology drugs, followed by central nervous system drugs. The company develops drugs for global use in Asia, Europe, and the United States.

Luye Pharma Group (HKSE:02186) Headlines

No Headlines